A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects

Trial Profile

A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs CF 301 (Primary)
  • Indications Bacteraemia; Bacterial endocarditis; Skin and soft tissue infections; Staphylococcal infections
  • Focus Adverse reactions; First in man
  • Sponsors ContraFect
  • Most Recent Events

    • 01 Jun 2017 New analyses of clinical data from this trial will be presented at the American Society for Microbiology (ASM) Microbe 2017 conference according to a ContraFect Corporation media release.
    • 25 Apr 2017 Results of long term immunology follow up, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 19 Apr 2017 Long term follow-up data from this trial will be presented at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), according to a ContraFect media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top